{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:31:20Z","timestamp":1785879080813,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.toxicon.2025.108605","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:08:21Z","timestamp":1759360101000},"page":"108605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Botulinum toxin as an effective rescue treatment after failure of anti-CGRP monoclonal antibodies in chronic migraine patients"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4554-8815","authenticated-orcid":false,"given":"Giovanni","family":"Ermanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tereshko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Belgrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luigi","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2025.108605_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-023-01567-4","article-title":"Future targets for migraine treatment beyond CGRP","volume":"24","author":"Al-Hassany","year":"2023","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib2","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/ene.14828","article-title":"Partial and nonresponders to onabotulinumtoxinA can benefit from anti\u2010CGRP monoclonal antibodies preventive treatment: a real\u2010world evidence study","volume":"28","author":"Alpuente","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2025.108605_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/toxins12120803","article-title":"Botulinum toxin in the treatment of headache","volume":"12","author":"Becker","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108605_bib4","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/head.13317","article-title":"The effect of OnabotulinumtoxinA on aura frequency and severity in patients with hemiplegic migraine: case series of 11 patients","volume":"58","author":"Chen","year":"2018","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double\u2010blind, randomized, placebo\u2010controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib7","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1093\/brain\/awac040","article-title":"The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?","volume":"145","author":"Ernstsen","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.toxicon.2025.108605_bib8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/03331024211018137","article-title":"CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis","volume":"41","author":"Frank","year":"2021","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108605_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.33588\/rn.7606.2022350","article-title":"Efecto beneficioso del cambio a un segundo anticuerpo monoclonal anti-CGRP en pacientes con migra\u00f1a no respondedores a un primero","volume":"76","author":"Fres\u00e1n Restituto","year":"2023","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.toxicon.2025.108605_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s10194-024-01721-6","article-title":"Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study","volume":"25","author":"Grazzi","year":"2024","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib11","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1007\/s10072-022-06195-5","article-title":"The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.toxicon.2025.108605_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1215","article-title":"CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta\u2010analysis","volume":"9","author":"Han","year":"2019","journal-title":"Brain Behav"},{"key":"10.1016\/j.toxicon.2025.108605_bib13","first-page":"1","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108605_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clineuro.2017.01.009","article-title":"Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis","volume":"154","author":"Hong","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.toxicon.2025.108605_bib15","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","article-title":"Mode and site of action of therapies targeting CGRP signaling","volume":"24","author":"Labastida-Ram\u00edrez","year":"2023","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13041-020-00580-x","article-title":"Cortical potentiation induced by calcitonin gene-related peptide (CGRP) in the insular cortex of adult mice","volume":"13","author":"Liu","year":"2020","journal-title":"Mol. Brain"},{"key":"10.1016\/j.toxicon.2025.108605_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.33588\/rn.7504.2021526","article-title":"Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migra\u00f1a. \u00bfTiene sentido probar otro?","volume":"75","author":"L\u00f3pez Moreno","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.toxicon.2025.108605_bib19","article-title":"Calcitonin gene\u2013related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: evidence from indirect treatment comparison","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.toxicon.2025.108605_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108605_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108605_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14728214.2024.2317778","article-title":"Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention","volume":"29","author":"Pellesi","year":"2024","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.toxicon.2025.108605_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/toxins16100427","article-title":"Onabotulinumtoxin A for the treatment of post-traumatic headache: is it better than Anti-CGRP antibodies?","volume":"16","author":"Pellesi","year":"2024","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108605_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache Federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40263-024-01086-z","article-title":"Synergism of Anti-CGRP monoclonal antibodies and OnabotulinumtoxinA in the treatment of chronic migraine: a real-world retrospective chart review","volume":"38","author":"Salim","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.toxicon.2025.108605_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40001-022-00716-w","article-title":"Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review","volume":"27","author":"Sevivas","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.toxicon.2025.108605_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918767697","article-title":"Chronic migraine: a process of dysmodulation and sensitization","volume":"14","author":"Su","year":"2018","journal-title":"Mol. Pain"},{"key":"10.1016\/j.toxicon.2025.108605_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npep.2015.03.006","article-title":"Migraine and neuropeptides","volume":"52","author":"Tajti","year":"2015","journal-title":"Neuropeptides"},{"key":"10.1016\/j.toxicon.2025.108605_bib29","doi-asserted-by":"crossref","first-page":"7329","DOI":"10.3390\/jcm12237329","article-title":"Comparative study of the efficacy of Anti-CGRP mAbs on migraineurs: analysis of the first year of therapy, 1-Month suspension period, and reprisal","volume":"12","author":"Tereshko","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.toxicon.2025.108605_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713471","article-title":"The anti-calcitonin gene-related peptide (Anti-CGRP) antibody fremanezumab reduces trigeminal neurons immunoreactive to CGRP and CGRP receptor components in rats","volume":"24","author":"Vogler","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxicon.2025.108605_bib31","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010740","article-title":"Central effects of erenumab in migraine patients: an event-related functional imaging study","volume":"95","author":"Ziegeler","year":"2020","journal-title":"Neurology"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125003800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125003800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T01:56:02Z","timestamp":1764640562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010125003800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0041010125003800"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108605","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum toxin as an effective rescue treatment after failure of anti-CGRP monoclonal antibodies in chronic migraine patients","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108605"}}